Katharine J Bar, MD
Associate Professor of Medicine (Infectious Diseases)
Attending Physician, Infectious Diseases, Hospital of the University of Pennsylvania
Physician, International Travel Medicine Clinic, Perelman Center for Advanced Medicine
Director, Penn CFAR Viral and Molecular Core
Department: Medicine
Graduate Group Affiliations
Contact information
502 D Johnson Pavilion
3610 Hamilton Walk
Philadelphia, PA 19104-6073
3610 Hamilton Walk
Philadelphia, PA 19104-6073
Office: (215) 573-8497
Fax: (215) 349-5111
Fax: (215) 349-5111
Email:
bark@pennmedicine.upenn.edu
bark@pennmedicine.upenn.edu
Education:
BA (Biochemistry and African History, Honors)
Northwestern University, Evanston, IL, 1997.
MD
University of Iowa College of Medicine, Iowa City, IA, 2002.
Permanent linkBA (Biochemistry and African History, Honors)
Northwestern University, Evanston, IL, 1997.
MD
University of Iowa College of Medicine, Iowa City, IA, 2002.
Description of Clinical Expertise
HIV care, general infectious disease careDescription of Research Expertise
The Bar Lab studies novel approaches to HIV prevention and cure. Our current research focuses on:(i) characterizing the viral dynamics and host immune responses during virus suppression and treatment interruption,
(ii) developing NHP models that faithfully recapitulate HIV-1 latency and rebound, and
(iii) developing antibody-based interventions.
Selected Publications
Bauer A, Lindemuth E, Marino FE, Krause R, Joy J, Docken SS, Mallick S, McCormick K, Holt C, Georgiev I, Felber B, Keele BF, Veazey R, Davenport MP, Li H, Shaw GM, Bar KJ.: Adaptation of a transmitted/founder simian-human immunodeficiency virus for enhanced replication in rhesus macaques. PLoS Pathog 19(7): e1011059, Jul 2023.Dross S, Venkataraman R, Patel S, Huang ML, Bollard CM, Rosati M, Pavlakis GN, Felber BK, Bar KJ, Shaw GM, Jerome KR, Mullins JI, Kiem HP, Fuller DH, Peterson CW: Efficient ex vivo expansion of conserved element vaccine-specific CD8+ T-cells from SHIV-infected, ART-suppressed nonhuman primates. Front Immunol 3(14): 1188018, May 2023.
Li C, Anderson AK, Wang H, Gil S, Kim J, Huang L, Germond A, Baldessari A, Nelson V, Bar KJ, Peterson CW, Bui J, Kiem HP, Lieber A: Stable HIV decoy receptor expression after in vivo HSC transduction in mice and NHPs: Safety and efficacy in protection from SHIV. Mol Ther 31(4): 1059-1073, April 2023.
Wu VH, Nordin JML, Nguyen S, Joy J, Mampe F, Del Rio Estrada PM, Torres-Ruiz F, González-Navarro M, Luna-Villalobos YA, Ávila-Ríos S, Reyes-Terán G, Tebas P, Montaner LJ, Bar KJ, Vella LA, Betts MR.: Profound phenotypic and epigenetic heterogeneity of the HIV-1-infected CD4+ T cell reservoir. Nat Immunol 24(2): 359-370, Feb 2023.
Wu VH, Nordin JML, Nguyen S, Joy J, Mampe F, Del Rio Estrada PM, Torres-Ruiz F, González-Navarro M, Luna-Villalobos YA, Ávila-Ríos S, Reyes-Terán G, Tebas P, Montaner LJ, Bar KJ, Vella LA, Betts MR: Profound phenotypic and epigenetic heterogeneity of the HIV-1-infected CD4+ T cell reservoir. Nat Immunol Page: doi: 10.1038/s41590-022-01371-3, December 2022.
Herman JD, Wang C, Burke JS, Zur Y, Compere H, Kang J, Macvicar R, Taylor S, Shin S, Frank I, Siegel D, Tebas P, Choi GH, Shaw PA, Yoon H, Pirofski LA, Julg BD, Bar KJ, Lauffenburger D, Alter G. : Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy. Cell Rep Med 3(11): doi: 10.1016/j.xcrm.2022.100811, November 2022.
Daniell H, Nair SK, Shi Y, Wang P, Montone KT, Shaw PA, Choi GH, Ghani D, Weaver J, Rader DJ, Margulies KB, Collman RG, Laudanski K, Bar KJ: Decrease in Angiotensin-Converting Enzyme activity but not concentration in plasma/lungs in COVID-19 patients offers clues for diagnosis/treatment. Mol Ther Methods Clin Dev 8(26): 266-278, September 2022.
Nelson AN, Dennis M, Mangold JF, Li K, Saha PT, Cronin K, Cross KA, Kumar A, Mangan RJ, Shaw GM, Bar KJ, Haynes B, Moody AM, Munir Alam S, Pollara J, Hudgens MG, Van Rompay KKA, De Paris K, Permar SR.: Leveraging antigenic seniority for maternal vaccination to prevent mother-to-child transmission of HIV-1. NPJ Vaccines 7(1:87), July 2022.
Herman GA, O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Musser BJ, Davis JD, Turner KC, Mahmood A, Hooper AT, Hamilton JD, Parrino J, Subramaniam D, Baum A, Kyratsous CA, DiCioccio AT, Stahl N, Braunstein N, Yancopoulos GD, Weinreich DM; COVID-19 Phase 3 Prevention Trial Team.: Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis S1473-3099(22), July 2022.
Shaw PA, Yang JB, Mowery DL, Schriver ER, Mahoney KB, Bar KJ, Ellenberg SS: Determinants of hospital outcomes for patients with COVID-19 in the University of Pennsylvania Health System. PLoS One 17(5), May 2022.